Daan Westenbrink is a clinical cardiologist and a translational scientist at the University Medical Center Groningen. He is a junior PI in the Double Dosis consortium and participated in the Dutch Cardiovascular Alliance as board member and chair of Young@Heart.
He studied medicine at the University of Groningen and completed a PhD program at the University of Groningen and a post-doctoral fellowship at the University of California San Diego, USA. He is licensed as a clinical pharmacologist and is subspecialized in heart failure and cardiac MRI. His research group studies the origins of mitochondrial dysfunction in heart failure with the intention to develop metabolic therapies for heart failure. The research in Groningen involves functional studies in isolated mitochondria and cultured cardiomyocytes as well as intervention studies in murine models. His group also uses advanced MRI techniques to study the effects of drugs on mitochondrial function in patients with heart failure.